American Oriental Bioengineering (广西博科药业) reported higher Q2 revenues, though the company’s improved sales did not translate to the bottom line. American Oriental’s revenues rose 21% in the period to $71.2 million, but net income slipped 5% lower to $13.2 million. AOB also announced a new product for rhinitis and allergies, Jingwei Capsules, which it compared to Schering-Plough's Claritine. More details...

Stock Symbol: (NYSE: AOB)